Navigation Links
Vaccine Pipeline Database: 1-Year Subscription
Date:10/6/2011

NEW YORK, Oct. 6, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Vaccine Pipeline Database: 1-Year Subscription

http://www.reportlinker.com/p0652031/Vaccine-Pipeline-Database-1-Year-Subscription.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Product description

Subscription to La Merie's proprietary Vaccine Pipeline Database provides online access to more than 1,200 project entries for prophylactic and therapeutic vaccines on the market and in research & development. Each project is specified for its Target or Mechanism of Action, Therapeutic Area and R&D Phase. Use of the R&D database of vaccines is intuitive. Data sets of interest can be printed and exported. Projects are being updated continuously. The R&D history of each project with online references of information sources can be viewed and printed. The projects can be segmented into Territories, Therapeutic Areas and R&D Phases. An advanced search function allows to combine search parameters. A scroll down menu for predefined targets conveniently selects projects of interest. By clicking on column heads of the project list, projects can be arranged in ascending or descending alphabetical or numerical order, e.g. for phase, product category or company name. Sample screenshots illustrate the database.

Purchase of the subscription provides a 1-year online access to the data of the Antibody Pipeline Database. Credentials to access the database will be sent by e-mail within 24 hours after purchase.

Benefits from the Antibody Pipeline Database:

-New database (since 2008) with no historical burden

-Intuitive use

-Designed for structured searches

-Focused on targets, therapeutic areas and R&D phases

-Ideal for competitor analysis (companies, targets, product categories)

-Cost-effective and rapid solution for benchmarking

-Identification of licensing candidates

Project listing in a tabular format:

-Drug Codes

-Target / Mechanism of Action

-Class of Compound

-Product Category

-Company

-Territory

-Therapeutic Area

-Indication

-R&D Phase

Therapeutic Areas:

Cardiovascular & blood

Dermatology

Gastrointestinal

Genitourinary, renal & gynecology

Infectious & toxicology

Metabolism & endocrine

Neurology & psychiatry

Oncology

Ophthalmology & otorhinolaryngology

Orthopedics, dental, anesthesia & surgery

Pulmonary & respiratory

Rheumatoid & autoimmune

Examples of Predefined Targets of the Scroll Down Menu:

Hepatitis Vaccines

Influenza Vaccines

Herpes Virus Vaccines

Staphylococcal Aureus Vaccines

Streptococcal Vaccines

Pseudomonas Aeruginosa Vaccines

Cytomegalovirus (CMV) Vaccines

Tuberculosis Vaccines

Anthrax Vaccines

Respiratory Syncytial Virus (RSV) Vaccines

Human Papilloma Virus (HPV) Vaccines

Malaria Vaccines

Dengue Virus Vaccines

Human Immunodeficiency Virus (HIV) Vaccines

Therapeutic Cancer Vaccines

To order this report:

Drug and Medication Industry: Vaccine Pipeline Database: 1-Year Subscription

Drug and Medication Business News

More  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Inovio Pharmaceuticals Synthetic Vaccine for Cancer Recognized as Most Promising Research at Global Vaccine Congress
2. Triple Analysis: Apoptosis, Cancer Vaccines and Antibodies
3. Synthetic Genomics Vaccines, Inc. Hires Vaccine Executive Sammy J. Farah as President
4. Inovio Pharmaceuticals Enters Collaboration With U.S. Dept. of Homeland Security to Assess Foot & Mouth Disease Synthetic Vaccines Potential to Help Ensure Nations Food Supply Safety
5. Nations Pharmacists Ready to Administer Seasonal Flu Vaccines
6. GlycoVaxyns Staphylococcus aureus Bioconjugate Vaccine Candidate Protects Mice Against Invasive S. aureus Infection
7. Inovio Pharmaceuticals Completes PENNVAX™-B HIV Vaccine Phase I Study, Demonstrates Best-in-Class T-Cell Immune Responses
8. Initial Trial of Sanarias Malaria Vaccine Yields Positive Results
9. Manufacturing of Vaccines - Cell Culture Technology Gradually Replacing Egg-Based Manufacturing
10. Anthem Blue Cross Kicks Off Statewide Series Of Free Whooping Cough Vaccine Clinics In Watts On Saturday
11. Pevion Grants CSL Option Right to its Therapeutic Candida Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... ORANGEBURG, N.Y. , Sept. 6, 2017   PDI ... today announced it will host an educational session focused ... line-associated bloodstream infection (CLABSI) prevention at the 2017 Annual ... meeting, which will take place at the ... Arizona from Sept. 16-19, will also feature ...
(Date:9/6/2017)... , Sept. 6, 2017 Eli Lilly ... it will present new data for galcanezumab and lasmiditan, ... of the International Headache Society (IHC) taking place Sept. ... Lilly will highlight new, long-term data from an ... doses of galcanezumab (120 mg and 240 mg) for ...
(Date:9/5/2017)... -- Xyntek Inc. has announced another milestone in their continued growth and success of ... growing demands of customer engagements regionally.  ... Midwest office is located at 318 West Adams Street, Suite 1528, Chicago, IL ... Xyntek's recently opened Midwest ... In ...
Breaking Medicine Technology:
(Date:9/21/2017)... ... September 21, 2017 , ... Demonstrating a consistent ... health departments have been awarded five-year accreditation status through the Public Health ... being served by a PHAB-accredited health department now extend to more than ...
(Date:9/21/2017)... ... September 21, 2017 , ... Preora Diagnostics Inc. ... screening tests, has received two prestigious recognitions that acknowledge the promise of its ... Preora has been named a Top 100 Finalist for the 16th annual ...
(Date:9/21/2017)... Fort Payne, AL (PRWEB) , ... September 21, ... ... financial preparation provider with offices serving communities in northern Alabama and Georgia, is ... positive breast cancer prevention by utilizing modern early detection methods. , US ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... of the Best Places to Work in the Research Triangle for 2017. , ... nominated, a company had to meet a threshold in employee participation--a percentage that ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... exhibitors at the East-coast edition of MarTech: The Marketing Tech Conference October 2–4, ... together more than 40 speakers — representing such thought-leading companies as JP ...
Breaking Medicine News(10 mins):